Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

Patent metadata

Field	Value
Publication number	US-10040799-B2
Application number	US-201715789645-A
Country	US
Kind code	B2
Filing date	Oct 20, 2017
Priority date	Jul 1, 2015
Publication date	Aug 7, 2018
Grant date	Aug 7, 2018

Abstract

Disclosed are new small molecules having a 4-methylpyrrrolo[1,2-a]pyrimidine-8-carboxamide core structure and the uses thereof for modulating glucocerebrosidase activity. Also disclosed are pharmaceutical compositions comprising the small molecules which may be administered in methods of treating diseases or disorders associated with glucocerebrosidase activity, including neurological diseases and disorders such as Gaucher's disease and Parkinson's disease. The small molecules may contain a fluorophore or may be conjugated to a fluorophore in order to prepare a fluorescent probe for use in high throughput screening methods to identify new modulators of glucocerebrosidase activity via fluorescence polarization.

First claim

We claim:

1. A method for treating Gaucher's disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound or a salt or solvate thereof having a Formula I:

wherein:
R 1 is hydrogen, an alkyl group, an alkylhydroxyl group, a carboxyl group, a 2,5-dioxopyrrolidinyl-1-yl-carboxylate group; an alkylamino group; an alkyl-N,N-dialkyl amino group; an alkyl-alkyoxy-amino group; an alkyl-alkyoxy-alkoxy-amino group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-morpholine group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-1-alkylpyrrolidine group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-cyclohexyl group; and an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-cyclobutyl group.

2. A method for treating Gaucher's disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound or a salt or solvate thereof having a formula selected from:

3. A method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound or a salt or solvate thereof having a Formula I:

wherein:
R 1 is hydrogen, an alkyl group, an alkylhydroxyl group, a carboxyl group, a 2,5-dioxopyrrolidinyl-1-yl-carboxylate group; an alkylamino group; an alkyl-N,N-dialkyl amino group; an alkyl-alkyoxy-amino group; an alkyl-alkyoxy-alkoxy-amino group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-morpholine group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-1-alkylpyrrolidine group; an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-cyclohexyl group; and an alkyl-alkyoxy-alkoxy-carboxamide-alkyl-cyclobutyl group.

4. A method for treating Parkinson's disease in a subject in need thereof, the method comprising administering to the subject a pharmaceutical composition comprising a compound or a salt or solvate thereof having a formula selected from:

Assignees

• Univ Northwestern

Inventors

• Krainc Dimitri
• Silverman Richard B
• Zheng Jianbin

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K9/2059

  Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin · CPC title

• A61P25/16

  Anti-Parkinson drugs · CPC title

• A61K47/26

  Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin · CPC title

• G01N2800/28

  Neurological disorders · CPC title